Research stack

Tesamorelin Visceral Adipose Reduction (Falutz Protocol)

Visceral adipose tissue reduction using the GHRH analog tesamorelin at the pivotal-trial dose.

Component peptides

Visceral adipose reduction with a GHRH analog at the pivotal-trial dose.

GHRH-analog signalling restores pulsatile endogenous GH secretion, which preferentially mobilizes visceral adipose tissue.

Tesamorelin — 2 mg once daily subcutaneous, evening, continuous for 26 weeks.

Last updated: 2026-09-15

Component peptides	Tesamorelin
Duration reported	26 weeks
Cycle pattern	26 weeks continuous, per pivotal trials
Difficulty	intermediate
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.